<DOC>
	<DOC>NCT00932841</DOC>
	<brief_summary>The goal of this study is to determine whether the oral administration of the probiotic VSL#3 under randomized, placebo-controlled conditions will improve symptoms of irritable bowel syndrome in children, safely.</brief_summary>
	<brief_title>The Use of VSL#3 in Irritable Bowel Syndrome in Children</brief_title>
	<detailed_description>Determine the safety and efficacy of different doses of VSL#3 in the treatment of children with irritable bowel syndrome: Children will be recruited from the pediatric gastroenterology clinic at The Children's Medical Center in Dayton, Ohio. Eighty four children will be enrolled in this controlled, double-blinded, randomized study. All children will have had a prior evaluation by a pediatric gastroenterologist who has diagnosed these patients with irritable bowel syndrome and excluded organic disease as a cause of the child's abdominal pain.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>All children should fulfill Rome ll criteria for IBS. Organic disease has been excluded. Age 1318 years. Have active symptoms for at least 2 weeks prior to randomization. A minimum of 4.0 on the 7point Likert scale for the two weeks prior to randomization on the GSRSIBS composite pain score will be required. Diarrhea predominant IBS: Diarrhea is defined as increased stool frequency more than 3 times daily or change in form to loose or watery stools. Children not fulfilling the inclusion criteria. Children receiving medication for the treatment of irritable bowel syndrome within 2 weeks of randomization. Children receiving antibiotic therapy or other probiotic agents within 4 weeks of randomization. Children receiving other medication known to cause abdominal pain. Children diagnosed with any of the following GI disorders: IBD (Crohn's disease or UC), Celiac disease, Gastroparesis, abdominal adhesions, Gastrointestinal perforation, Gastrointestinal obstruction and/or stricture, chronic or recurrent pancreatitis. Children who had undergone previous abdominal surgery (with the exception of uncomplicated appendectomy or cholecystectomy greater than or equal to 6 months prior to enrollment). Children with a history of any disease that may affect bowel motility such as diabetes mellitus, or poorly controlled hypo/hyperthyroidism. Children with immune deficiency, on immunesuppressants, or have active psychiatric, neurological, metabolic, renal, hepatic, infectious, hematological, cardiovascular or pulmonary disease. Children with a history of malignancy. Pregnancy. Children with history of allergy to maize or probiotics.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>